Back to top
more

Evofem Biosciences (EVFM)

(Delayed Data from OTC)

$0.02 USD

0.02
477,335

0.00 (25.35%)

Updated Apr 26, 2024 01:48 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 30% (75 out of 252)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

0 items in cart

Evofem Biosciences, Inc. [EVFM]

Reports for Purchase

Showing records 1 - 20 ( 118 total )

Company: Evofem Biosciences, Inc.

Industry: Medical - Biomedical and Genetics

Record: 1

02/27/2023

Company Report

Pages: 4

Dropping Coverage

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 5.00

Research Provided by a Third Party

Company: Evofem Biosciences, Inc.

Industry: Medical - Biomedical and Genetics

Record: 2

08/15/2022

Company Report

Pages: 5

Phexxi Growth; Reverse Split Implemented; 2Q22 Financials; Raising PT to $4

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 5.00

Research Provided by a Third Party

Company: Evofem Biosciences, Inc.

Industry: Medical - Biomedical and Genetics

Record: 3

02/10/2022

Company Report

Pages: 5

Qualified Infectious Disease Product Status Awarded; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 5.00

Research Provided by a Third Party

Company: Evofem Biosciences, Inc.

Industry: Medical - Biomedical and Genetics

Record: 4

01/31/2022

Company Report

Pages: 5

4Q21 Phexxi Preliminary Performance Packs Punch; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 5.00

Research Provided by a Third Party

Company: Evofem Biosciences, Inc.

Industry: Medical - Biomedical and Genetics

Record: 5

01/13/2022

Daily Note

Pages: 5

Phexxi Market Access Expansion via Government Guidance; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 5.00

Research Provided by a Third Party

Company: Evofem Biosciences, Inc.

Industry: Medical - Biomedical and Genetics

Record: 6

12/15/2021

Company Report

Pages: 5

Revenue Growth Anticipated; Operating Expense Control; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 5.00

Research Provided by a Third Party

Company: Evofem Biosciences, Inc.

Industry: Medical - Biomedical and Genetics

Record: 7

11/16/2021

Company Report

Pages: 5

Top- and Bottom-Line Miss; Gross-to-Nets Challenges; Lowering PT to $2

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 5.00

Research Provided by a Third Party

Company: Evofem Biosciences, Inc.

Industry: Medical - Biomedical and Genetics

Record: 8

10/21/2021

Company Report

Pages: 5

Marketing Campaign Impact; Preferred Stock Offering; Reducing PT to $2.50

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 5.00

Research Provided by a Third Party

Company: Evofem Biosciences, Inc.

Industry: Medical - Biomedical and Genetics

Record: 9

09/28/2021

Company Report

Pages: 10

ValuEngine Detailed Valuation Report for EVFM

Provider: ValuEngine, Inc

Analyst: Research Department

Price: 25.00

Research Provided by a Third Party

Company: Evofem Biosciences, Inc.

Industry: Medical - Biomedical and Genetics

Record: 10

06/07/2021

Company Report

Pages: 5

Phexxi Awareness Building; Lowering PT to $4 Based on Dilution

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party

Company: Evofem Biosciences, Inc.

Industry: Medical - Biomedical and Genetics

Record: 11

03/08/2021

Company Report

Pages: 5

Phexxi Sales Slow Off the Blocks; 2020 Financial Results; Reducing PT to $7

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party

Company: Evofem Biosciences, Inc.

Industry: Medical - Biomedical and Genetics

Record: 12

02/19/2021

Company Report

Pages: 5

Phexxi Marketing Campaign Accelerates; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party

Company: Evofem Biosciences, Inc.

Industry: Medical - Biomedical and Genetics

Record: 13

12/21/2020

Company Report

Pages: 5

Phexxi Sales Trajectory Revamped; Modulating PT to $8

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party

Company: Evofem Biosciences, Inc.

Industry: Medical - Biomedical and Genetics

Record: 14

10/21/2020

Company Report

Pages: 5

EVO100 Pivotal Trial Initiated; Strategic Investment Secured; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party

Company: Evofem Biosciences, Inc.

Industry: Medical - Biomedical and Genetics

Record: 15

08/05/2020

Company Report

Pages: 5

2Q20 Financial Results Reported; Phexxi Launch Perspectives; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party

Company: Evofem Biosciences, Inc.

Industry: Medical - Biomedical and Genetics

Record: 16

06/09/2020

Company Report

Pages: 5

Cash Replenished for Long Haul; Modulating PT to $9

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party

Company: Evofem Biosciences, Inc.

Industry: Medical - Biomedical and Genetics

Record: 17

05/27/2020

Company Report

Pages: 5

Phexxi Wins FDA Approval; Spending to Rise Near-Term; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party

Company: Evofem Biosciences, Inc.

Industry: Medical - Biomedical and Genetics

Record: 18

05/07/2020

Company Report

Pages: 5

1Q20 Financials; Phexxi Approval Decision Imminent; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party

Company: Evofem Biosciences, Inc.

Industry: Medical - Biomedical and Genetics

Record: 19

05/06/2020

Company Report

Pages: 5

Convertible Note Facility Established; Awaiting Phexxi Approval; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party

Company: Evofem Biosciences, Inc.

Industry: Medical - Biomedical and Genetics

Record: 20

04/27/2020

Company Report

Pages: 5

AMPOWER Data Sets Accepted by ACOG; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party